Specific cPRC1 complexes are co-opted to mediate oncogenic gene repression in diffuse midline glioma

Richard PhillipsMarch 21, 2025

A Chemical Strategy toward Novel Brain-Penetrant EZH2 Inhibitors.

Liang R, Tomita D, Sasaki Y, Ginn J, Michino M, Huggins DJ, Baxt L, Kargman S, Shahid M, Aso K, Duggan M, Stamford AW, DeStanchina E, Liverton N, Meinke PT, Foley MA, Phillips RE. A Chemical Strategy toward Novel Brain-Penetrant EZH2 Inhibitors. ACS Med Chem Lett. 2022 Feb 10;13(3):377-387. [PMID:35300079]

Tarah B.December 8, 2022

Epigenomic Reprogramming as a Driver of Malignant Glioma.

Phillips RE, Soshnev A, Allis, CD. Epigenomic Reprogramming as a Driver of Malignant Glioma. Cancer Cell. 2020 Nov 9;38(5):647-660. [PMID: 32916125]

Tarah B.June 14, 2020

Target Identification Reveals Lanosterol Synthase as a Vulnerability in Glioma.

Phillips RE, Yang Y, Smith R, Thompson B, Yamasaki T, Soto-Feliciano Y, Funato K, Liang Y, Garcia-Bermudez J, Wang X, Garcia B, Yamasaki K, McDonald J, Birsoy K, Tabar V, Allis CD. Target Identification Reveals Lanosterol Synthase as a Vulnerability in Glioma. Proc Natl Acad Sci USA. 2019 Apr 16;116(16):7957-7962 [PMID: 30923116]

Tarah B.June 14, 2020

Management of Late Extraneural Recurrence of Medulloblastoma without High-Dose Chemotherapy.

Phillips RE, Curran KJ, Khakoo Y. Management of Late Extraneural Recurrence of Medulloblastoma without High-Dose Chemotherapy. J Neurooncol. 2015 Sep;124(3):523-4. [PMID: 26115616]

Tarah B.June 14, 2020